Menu Search
Equities

Grand Pharmaceutical Group Ltd

512:HKG.HS

Grand Pharmaceutical Group Ltd

Actions
  • Price (HKD)4.31
  • Today's Change-0.03 / -0.69%
  • Shares traded2.70m
  • 1 Year change-6.10%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in HKDIncome statement in HKDView more

Year on year Grand Pharmaceutical Group Ltd had net income fall -9.59% from 2.08bn to 1.88bn despite a 10.12% increase in revenues from 9.56bn to 10.53bn. An increase in the selling, general and administrative costs as a percentage of sales from 35.28% to 36.66% was a component in the falling net income despite rising revenues.
Gross margin59.00%
Net profit margin22.92%
Operating margin28.60%
Return on assets10.25%
Return on equity15.97%
Return on investment14.21%
More ▼

Cash flow in HKDView more

In 2023, cash reserves at Grand Pharmaceutical Group Ltd fell by 104.31m. However, the company earned 2.42bn from its operations for a Cash Flow Margin of 23.03%. In addition the company used 515.75m on investing activities and also paid 1.89bn in financing cash flows.
Cash flow per share0.8231
Price/Cash flow per share5.32
Book value per share4.43
Tangible book value per share3.49
More ▼

Balance sheet in HKDView more

Grand Pharmaceutical Group Ltd has a Debt to Total Capital ratio of 22.32%, a higher figure than the previous year's 6.48%.
Current ratio1.29
Quick ratio1.09
Total debt/total equity0.2906
Total debt/total capital0.2232
More ▼

Growth rates in HKD

SmartText is unavailable
Div yield(5 year avg)2.73%
Div growth rate (5 year)24.77%
Payout ratio (TTM)37.58%
EPS growth(5 years)15.13
EPS (TTM) vs
TTM 1 year ago		1.91
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.